skip to main content

Post-TAVI Antithrombotic Management — EECC MCQ

Instant feedback + full explanation. One question, done properly.

ModerateValvular Heart DiseasePost-TAVI Antithrombotic ManagementEECC

A 75-year-old man underwent TAVI 3 months ago and is currently on aspirin 75 mg daily. He has no AF or other indication for anticoagulation. Per the 2025 ESC/EACTS VHD Guidelines, what is the recommended antithrombotic strategy after TAVI without an indication for oral anticoagulation?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Single antiplatelet therapy (aspirin) alone

Explanation lettering: B = shown as A · E = shown as B · A = shown as E

Per the 2025 ESC/EACTS VHD Guidelines, single antiplatelet therapy (aspirin alone) is preferred after TAVI without another indication for OAC. DAPT is no longer recommended routinely (POPular TAVI trial). Low-dose rivaroxaban (C) showed harm in GALILEO. DOACs alone (D) are not indicated without specific indication. No antithrombotic therapy (E) is not recommended.

Reference: ESC/EACTS (2025): Guidelines for the Management of Valvular Heart Disease